Nefrootiline
Nefrootiline is a synthetic opioid analgesic developed by the pharmaceutical company Pfizer. It was initially introduced in the 1970s and was marketed under the brand name Nubain. Nefrootiline is a mu-opioid receptor agonist, meaning it binds to the mu-opioid receptors in the brain, which are responsible for producing the analgesic and euphoric effects of opioids.
The drug is available in various forms, including tablets, oral solutions, and injectable suspensions. It is
Like other opioids, nefrootiline carries a risk of dependence and abuse. It is classified as a Schedule
Nefrootiline has been studied for its potential use in the treatment of opioid-induced hyperalgesia, a condition
In recent years, nefrootiline has seen a resurgence in interest due to its potential as a treatment
Overall, nefrootiline is a valuable medication for managing pain, but its use must be carefully monitored due